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The Mother Lode of Liver Transplantation, With 
Particular Reference to Our New Journal 
Thomas E. Starzl 
W ith certification for inclusion in the Index Medicus, * Liver Transplantation and Surgery 
will enter an exponential phase of its development. 
Authors contributing to the Journal now will find 
their work accessible to literature search via the 
same informational panoply as other major publica-
tions. The Journal has obtained an additional edge 
by its designation as an official organ of the 
American Association for the Study of Liver Dis-
ease (AASLD). However, its most important advan-
tage is the richness of the material to which Liver 
Transplantation and Surgery has potential access. 
The reports about clinical liver transplantation 
that have filled the pages of the Journal until now 
constitute only the small tip of a large biological 
iceberg. Each member of the abdominal organ 
complex (Fig. 1) has anatomical and functional 
relationships with all the others. Probing into these 
interactions during the evolution ofliver transplan-
tation set off ripple effects at least as important for 
continuing creative research and development as 
the kind of minor refinements, case studies, and 
expressions of opinion about the procedure itself 
that quickly reach the point of diminishing returns. 
The argument can be made best with historical 
examples that continue to foster inquiry. 
Portal (Hepatotrophic) Physiology 
The possibility of transplanting the whole liver was 
first mentioned in the scientific literature in 1955 
by C. Stuart Welch of Albany, NY I Envisioning 
potential clinical application, Welch described the 
insertion of an auxiliary hepatic allograft into the 
right paravertebral gutter or pelvis of nonimmuno-
suppressed dogs (Fig. 2A). When the portal venous 
inflow was derived from the inferior vena cava as 
shown, the auxiliary grafts underwent rapid atro-
phy. Welchs misconception that the shrinkage was 
a manifestation of unmodified rejectionl .2 was not 
corrected until his experiments were repeated un-
der effective immunosuppression. 3 Although rejec-
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tion could be prevented, the atrophy was essen-
tially the same. 
It was then realized that there were liver-
supporting constituent(s) of splanchnic venous 
blood that were not available to the graft because 
they were efficiently removed with the first pass 
through the native liver.3 Histopathologically, the 
shrunken auxiliary liver deprived of splanchnic 
venous blood was indistinguishable from that 
caused in rats, dogs, and primates by portacaval 
shunting (Eck's fistula) (summarized in reference 4). 
Because it was difficult, and sometimes techni-
cally impossible, to divert splanchnic venous blood 
to an auxiliary liver, these observations pushed the 
pendulum of the early 1960s toward the ostensibly 
more radical operation of liver replacement. How-
ever, it was learned at the outset that a single 
(orthotopic) liver allograft also required normal 
portal revascularization for optimal results5 (Fig. 
3). The same principle applies today. If orthotopiC 
liver transplantation is performed in patients who 
have portal-systemic shunts, the shunts should be 
disconnected. In patients who have thrombosis or 
damage to their native portal veins, extension or 
jump grafts can be used to ensure delivery to the 
transplanted liver of the hormone- and nutrient-
rich splanchnic blood.69 Alternative procedures 
that augment portal flow by portal arterialization 
or transhepatic rerouting of venous blood (i.e., 
portacaval transposition) can improve circum-
stances, but the resulting liver phYSiology is not 
normal. 
The Mysterious Eck Fistula 
In 1961, Bollman,1O the world's leading authority 
on "meat intoxication" (hepatic encephalopathy) 
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Figure 1. The complex of intraabdominal viscera 
(center) functional and anatomic interrelations. 
(Reprinted with permission from Transplant Proc 
1996;28:2430-2432.) 
and other complications of portacaval shunting, 
wrote: "Tn the 83 years since it was first reported, 
the Eck fistula has been reasonably successful in 
hiding its secrets as well as giving rise to many 
additional questions fundamental to an understand-
ing of the functions of the intestine, liver, and 
brain."lo These previously enigmatic syndromes 
became comprehensible when insulin finally \vas 
proved in 1975 to be the most important hepatotro-
phie factor in splanchnic venous blood. 4.11 ,12 Until 
then, the entrenched dogma of hepatic physiology 
had been that the volume rather than the source of 
portal venous blood flow was the critical factor in 
hepatic homeostasis and control of liver mass (the 
flow hypothesis4). Now it was evident that the 
principal liability of the splanchnic diversion proce-
dures came from their placement of the liver in an 
insulinoprival state. 
The partial amelioration of Eck fistula morbidity 
by now augmentation procedures such as Child's 
portacaval transposition 13 or Fisher's portal arteri-
alization14 was explained. With these strategies, 
diluted insulin and other splanchniC hepatotrophic 
substances recirculated in systemic blood were 
made more available to the liver in proportion to 
the increased total hepatic blood flow. The double 
liver models, of which auxiliary liver transplanta-
tion was the prototype (Fig. 2), were crucial to this 
understanding. The well-known effiCiency of insu-
lin removal during the first pass through the liver 
made this and other visceral hepatotrophic mol-
ecules relatively unavailable for the allograft and 
thus exaggerated the effect of portal vein depriva-
tion. 15-20 
It was readily understood why total splanchniC 
venous diversion (i.e., portacaval shunting) was 
such an acute insult to the already damaged liver of 
patients with hepatic disease, particularly when 
there had been significant portal flow before. 
Although the identity of "liver-supporting sub-
stances" in portal blood was not known until a 
dozen years after the original auxiliary transplanta-
tion investigations, the circumstantial evidence 
B 
Figure 2. Double-liver and double-liver fragment 
models that have been critical for the elucidation 
of splanchnic hepatotrophic factors: (A) auxiliary 
liver transplantation; (8) partial portacaval trans-
position, separating the effect on the liver of 
systemic versus splanchnic portal inflow; (C) 
splanchnic venous division, separating the effect 
of venous return from upper and lower abdominal 
viscera; and (D) Eck fistula plus selective infusion 
of test substances to one or the other of 2 liver 
fragments. (Reprinted with permission from Hepa-
to logy 1994;20:747-757.) 
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Figure 3. Methods of venous reconstruction 
evaluated in 1958 through 1960 for canine ortho-
topic liver transplantation. (A) Reverse Eck fis-
tula; (8) anatomic reconstruction with portacaval 
shunting; (C) completely anatomic portal venous 
reconstruction. Optimal results were obtained 
only in C. (Reprinted with permission from Surg 
Gynecol Obstet 1960;111 :733-743.) 
that these molecules were present in splanchnic 
venous blood explained the advantage of selective 
portal diversion procedures such as the Warren 
shunt21 that included a lower postoperative inci-
dence of encephalopathy and liver failure. 22 
Until this time, most surgeons and hepatologists 
had assumed that the normal human liver func-
tioned essentially normally after portacaval shunt-
ing except [or hyperammonemia.23.24 This view 
was inconsistent with the striking hepatocyte atro-
phy (to half size), deglycogenation, and fatty infil-
tration demonstrated in both Eck fistula and double 
liver models during the 1960s and 1970s+,12,20 in all 
species studied, including baboons25 and hu-
mans,426 At the same time, there is a tripling of 
liver cell renewal. 4,]], ]2,25,27 Both the atrophic and 
hyperplastic alterations caused by the portaprival 
state are complete within 4 days in dogs and remain 
stable thereafter (Table l),u,12,IH,20 
The ultrastructure of the hepatocytes of the 
Table 1. Evolution of Changes in the~After Eck 
Fistula Surgery 
Time (d) Labeled Hepatocyte/1 ,000 Cell Size Units 
0 1.5 0.18 
1 1.5 0.17 
2 1.9 0.15 
3 3.2 0.12 
4 4.5 0.09 
60 4.5 0.09 
Composite data from references 11, 12, 19, and 28. 
portaprivalliver shows a striking disruption of the 
rough endoplasmic reticulum and depletion of the 
ribosomes,11,12,28,29 explaining a reduced synthesis 
of cholesterol and other lipid moieties, bile acids, 
urea, and presumably essentially all metabolites of 
hepatic origin (summarized in reference 4). De-
creased activity of the hepatic microsomal mixed 
function enzyme system for which multiple cyto-
chrome P-450 and P-448 species serve as terminal 
oxidases accounts [or other subtle but cumula-
tively massive degradations in hepatic function. 4 
Treatment of Liver-Based Inborn Errors 
of Metabolism 
With Portacaval Shunting 
Historically, portal diversion procedures were done 
only to treat complications of portal hypertension 
(variceal hemorrhage and ascites),4,22 or rarely to 
extend the resection margins of hepatobiliary-
pancreatic neoplasms. 23 ,24 Their use was now ex-
tended to the palliation of three congenital inborn 
errors of metabolism: glycogen-storage disease,30,3] 
familial hypercholesterolemia,26,32 and (Xl-antitryp-
sin deficiency.33,34 Because each of these errors can 
be corrected far more effectively by liver transplan-
tation,35.39 their treatment with portacaval shunt-
ing has been abandoned. Between 1965 and 1980 
however, shunt surgery was the safest therap; 
available. 4 
The governing concept with glycogen-storage 
disease and (Xl-antitrypsin deficiency was that por-
tacaval shunting selectively damaged the rough 
endoplasmic reticulum, where the synthetiC pro-
cesses of the liver are concentrated, without a 
commensurate diminution in hepatic excretory 
function or in reduction of resorption of the 
abnormal metabolic deposits. There was a similar 
mechanism in familial hypercholesterolemia. The 
palliation in this disease came from the >80% 
reduction in hepatiC lipid synthesis caused by 
portacaval shunting in rats, dogs, baboons, and 
humans (summarized in references 4 and 32). In 
patients with homozygous familial hypercholester-
olemia, the result was a decline by a third to a half 
or more of the astronomical plasma cholesterol and 
low-density lipoprotein (LDL) levels (l,000 mg! 
dL).26,32 \Vithout treatment, these patients die in 
their teens or early 20s of coronary atherosclerosis 
and other complications of premature atherosclero-
sis. 
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The Shift to Liver Replacement 
The rationale was obvious for using liver replace-
ment rather than portacaval shunting to treat the 
principal glycogen-storage diseases and ex I-antitryp-
sin deficiency. However, liver replacement was not 
used successfully for any inborn error until the 
correction of Wilson's disease4l1 ,41 in the early 
1970s. Nevertheless, the biochemical basis for case 
selection had begun to be laid in 1956, when 
structural abnormalities of metabolites and espe-
cially deficient enzymes that regulate the produc-
tion or elimination of gene products were used for 
the first time to define clinical disorders and 
determine which were "liver based." The first to be 
defined biochemically was glycogen-storage dis-
ease.42 
Meanwhile, it was learned in the 1960s that 
although the nonparenchymal "passenger leuko-
cytes" of the orthotopically transplanted liver were 
promptly replaced by those of the recipient,43 the 
hepatocytes remained of donor phenotype and 
permanently endowed the recipient with the do-
nor's metabolic profile. 3,43,44 Armed with this infor-
mation, compilation began of the hepatic-based 
inborn errors that could be cured with liver replace-
ment. The list of diseases successfully treated with 
transplantation by 1989 had grown to more than 
two dozen. 3R 
In some of these disorders, however, the trans-
plantation itself became the means by which the 
liver's role was clarified. Familial hypercholesterol-
emia was a prime example, and a highly controver-
sial one. Because we had demonstrated that end-to-
side portacaval shunting caused a marked decrease 
in blood cholesterol levels of normal dogs,2° and 
that the same thing occurred in patients with 
glycogen-storage disease3l and familial hypercholes-
terolemia,26 we concluded by 1973 that the liver 
controlled cholesterol homeostasis. If this were 
true, the corollary was that hepatic replacement 
would cure familial hypercholesterolemia. Conse-
quently, we listed familial hypercholesterolemia 
from 1973 on as an indication for liver transplanta-
tion. However, the proposal was initially consid-
ered to be so irrational that it could not be acted on 
until more than a decade later.45 
The reason was that our hypotheSis of hepatic 
cholesterol control was seemingly discredited by 
the discovery of Goldstein and Brown46 at South-
western University (Dallas, TX) that fibroblasts 
and all cells in patients \vith familial hypercholester-
olemia were deficient in the lDl receptors to 
which circulating cholesterol-rich complexes are 
bound in the process of elimination. It was not 
possible to reconcile this fundamental discovery 
with the circumstantial evidence of hepatic choles-
terol homeostasis obtained from the auxiliary liver 
and Eck fistula investigations. Clarification finally 
came from a series of reports from Goldstein and 
Brown between 1977 and 1981 (summarized in 
reference 47) showing that a large proportion of 
binding of cholesterol complex occurred in the 
liver. 
Residual doubts about the liver's role in choles-
terol homeostasis were removed dramatically on 
Valentine's Day 1984, when a 6-year-old patient of 
Goldstein and Brown who had irreversible cardiac 
damage from the premature atherosclerosis of ho-
mozygous familial hypercholesterolemia under-
went combined heart (by Henry T. Bahnson) and 
liver (by Byers Shaw) transplantation at the Univer-
sity of Pittsburgh.48 The girl's serum cholesterol, 
which had been 1,000 mg/dl, fell to 250 mg/dl 
within a few days49.50 and remained at this level 
until her death 6.5 years later. For their elucidation 
of cholesterol metabolism, including its hepatic 
modulation in disease and health, Brown and 
Goldstein were awarded the Nobel Prize in Decem-
ber 1985. 
Control of Liver Volume 
and Regeneration 
The essence of the double liver models (Fig. 
2B-2D) that derived from the auxiliary liver trans-
plant preparation (Fig. 2A) was division of the 
animal's own liver into competing fragments in 
which one liver fragment dominates the other by 
its avid clearance ofhepatotrophic substances deliv-
ered through the portal blood supply (see previous 
section). With the final model (Fig. 2D), both liver 
fragments were detached from any portal venous 
innow. Test substances were then infused into 
either the right or left portal vein branch. Seven 
growth factors in addition to insulin have been 
shown to prevent completely the changes caused 
by Eck fistula in the infused (but not the other) 
liver fragment. 51 In addition, two agents were 
found to have an opposite Cantihepatotrophic) 
action (Table 2). These molecules in various combi-
nations under different circumstances can pro-
foundly affect liver structure, volume, and the 
capacity for regeneration in addition to hepatic 
function. 
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Table 2. Growth Factors Revealed by Studies by 
the Eck Fistula Double-Fragment Model 
Shown in Figure 3D 
Stimulatory 
Hormones 
Insulin 
Growth factors: 
Cytosol substrate and ALR 
Insulin-like growth factor II 
Transforming growth factor-C'* 
Hepatic growth factor* 
Immunosuppressants 
Cyclosporine 
FK 506 (Tacrolimus) 
Immunophilins 
FK 506-binding protein 
(FKBP12) 
Inhibitory 
Growth factors 
TGF-fH 
Immunosuppression 
Rapamycint 
NOTE. Discoveries were made between 1975 and 
1995 (see reference 51 for annotation). 
'Mitogenic in tissue culture. 
tlnhibitory in tissue culture. 
Because only two of the eight hepatotrophic 
factors (transforming growth factor a [TGF-a] and 
hepatocyte growth factor [HGF]) stimulate mitoses 
in tissue culture, the hepatotrophic effects of the 
other six had not been recognized with in vitro 
techniques. For hepatologists and immunologists 
as well as for transplant surgeons, it was particu-
larly Significant that the T-cell-directed immuno-
suppressants cyclosporine and tacrolimus are hepa-
totrophic, whereas rapamycin and transforming 
growth factor 13 (TGF-I3) make up the short list of 
potent antihepatotrophic factors. The obvious im-
plication of potential immunological modulation 
in the control of hepatic volume and regeneration 
has only begun to be explored. 52.53 
The most elusive of the six "occult" growth 
factors that are nonmitogenic in tissue culture was 
the molecule called "augmenter of liver regenera-
tion" (ALR) , which is found in regenerating ratR~ 
and dog2855 livers after partial hepatectomy and in 
the hyperplastic livers of weanling rats.51 ,54.56 The 
purification of a crude hepatic cytosoP8 to 
>800,00051 and cloning after 16 years of effort in 
our laboratories56 added another important compo-
nent to the complex network of modulators, both 
stimulatory and suppressive, which regulate hepa-
tocyte proliferation and hepatic regeneration at the 
organ leveL ALR is a unique, heat-stable peptide 
whose gene shows 50% homology with the dual-
function nuclear gene ERV1 of the yeast Saccharo-
myces cerevisiae (baker's yeast). 57 
The ERV1 gene is required for oxidative phos-
phorylation (respiratory chain) by the yeast and 
also is essential for mitosis, which ceases in 3 to 4 
days after gene deletion. 57 If, as we believe, ALR is 
the mammalian homologue of ERV1, it is apt to be 
a major growth-regulatory gene, including at the 
organogenesis leveL After the discovery of the ALR 
gene in the rat,56 we identified the mouse and 
human ALR genes (and the protein products).58 
These were found in all three mammalian species 
to be highly conserved and preferentially expressed 
in the liver and the testis. 56.58 
The ALR gene maps to the mouse chromosome 
17, in a region systemic with human chromosome 
16, where the allele-rich Tit region involved in 
spermatogenesis is located. 58 Thus the physiologi-
cal properties of the ALR protein almost certainly 
are not limited to liver regeneration. We have 
suggested involvement of ALR in the synthesis or 
stability of the nuclear and mitochondrial tran-
scripts that are present in actively regenerating 
cells, particularly the germ cells of the testis.'s The 
fact that so little is yet known about ALR compared 
with the other hepatotrophic factors makes this 
gene and its peptide inviting targets for basic and 
clinical inquiries. The potential value of ALR in the 
treatment of fulminant hepatic failure or in artifi-
cialliver support systems has yet to be determined. 
Anatomic Research 
As a result of liver transplantation, interest was 
awakened in "anatomic trivia" such as the blood 
supply of the extrahepatiC bile ducts, variations of 
the arterial and venous systems of the liver, and 
biliary tract anomalies that mandated modifica-
tions of standard transplant surgery. Knowledge of 
intrahepatic anatomy also assumed new clinical 
relevance. 
The surgical-anatomic units that theoretically 
could be removed with partial liver resections had 
been incrementally clarified between 1927 and 
1957 by the anatomic research of McIndoe and 
Counseller,59 Hjortsjo,60 Healey,6! Healey and 
Schroy,b2 Couninaud,b3 and Goldsmith and Wood-
burne.64 Until the 1970s, however, only three 
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standard procedures had exploited this infonna-
tion for "controlled resections" in which the target 
specimens were devascularized in the hilum before 
entering the liver parenchyma: right and left lobec-
tomy and left lateral segmentectomy (Fig. 4). 
A fourth operation in which all of the liver to the 
right of the falciform ligament was removed (ap-
proximately 80%-85% of the organ) had been 
reported between 1951 and 1953 by Wangen-
steen,65 Lortat-Jacob and Robert,66 and Quattle-
baum(17 Enthusiasm for performance of this proce-
dure (right trisegmentectomy, also known as 
extended right lobectomy68) had been dampened 
by an unacceptably high mortality rate (up to 
40%).6971 Lack of concentrated experience with 
the difficult operation was the reason. 
This changed when patients began to be referred 
to the University of Colorado in the late 19605 as 
candidates for orthotopic liver transplantation be-
cause of "unresectable hepatic tumors." Many of 
these malignancies could be removed instead with 
right trisegmentectomy. By 1974, 14 such patients 
had undergone the nontransplantation option with 
no surgical mortality. 72 Safe performance of right 
trisegmentectomy required an understanding of 
the anatomy in the umbilical fissure that is encoun-
RighI 
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Figure 4. The four types of partial hepatectomy 
most commonly performed with hilar control. 
Note that there are only four common resections: 
right and left lobectomy, right trisegmentectomy, 
and left lateral segmentectomy. (Reprinted with 
permission from Surg Gynecol Obstet 1975;141: 
429-438.) 
~IK--
Figure 5. Separation in the coronal plain of the 
anterior from the posterior segment of the right 
lobe during left trisegmentectomy after revascular-
ization of the left lobe. Note that the dissecting 
finger is kept anterior to the right hepatic vein, the 
left and middle hepatic vein having been ligated 
or sutured. (Reprinted with permission from Surg 
Gynecol Obstet 1982;155:21-27.) 
tered in dissecting the left branches of the portal 
triad. \Vhen 17 more cases were accrued with no 
deaths,a the procedure became a standard service. 
Left trisegmentectomy, a fifth variety of con-
trolled hepatic resection, also emerged from the 
liver transplantation clinics,?4 This operation in-
volves removal of the true left lobe of the liver in 
continuity with the anterior segment of the right 
lobe plus part or all of the caudate lobe. The 
dangerous phase of left trisegmentectomy, during 
the development of the coronal plane between the 
anterior and posterior segments of the right lobe 
(Fig. 5), is facilitated by cross-clamping of the 
portal triad (the Pringle maneuver). The resulting 
normothermic ischemia of the residual liver frag-
ment, which previously was considered acceptable 
for only 10 or 20 minutes, has been shown to be 
well tolerated for an hour or more by Huguet et 
al,75 a liver transplant surgeon who trained at the 
University of Colorado. 
Other liver transplant-derived strategies have 
been applied to hepatic resection, including in situ 
cooling of the totally devascularized liver, with or 
without venovenous bypass. In the opposite trans-
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fer of technology, the increasingly sophisticated 
resection techniques that evolved largely from liver 
transplantation experience have contributed to the 
safety of the partial liver transplantation tech-
niques pioneered by Henri Bismuth (Paris), Rudolf 
Pichlmayr (Hanover), Stephen Lynch and Russell 
Strong (Brisbane), and Christoph Broelsch (Chi-
cago, Hamburg). Most recently, the brilliant studies 
of Strasberg76 have shown that the science of pure 
gross anatomy is far from dead. 
The Biology of Cancer, With Particular 
Reference to PosUransplantation 
Lymphoproliferative Disorders 
To succeed with organ transplantation, it is neces-
sary to alter drastically the immune system of the 
recipient and thereby reduce one of the natural 
defenses against malignant tumors. By the late 
1960s, there was evidence that the loss of tumor 
surveillance in immunosuppressed organ recipi-
ents could result in 0) accidcntal engraftment of 
donor malignanCies, (2) accelerated growth of 
microscopic metastatic neoplasms of either donor 
or recipient origin, and (3) increased incidence of 
de novo malignancies. i7 ,78 Although real, the risks 
from the first two complications have been mini-
mized by appropriate donor and recipient screen-
ing. 
In contrast, a striking increase in de novo 
malignancies called posttransplantation lymphopro-
liferative disorders (PTLD) has occurred, particu-
larly after the advent of the T-cell-directed agents 
cyclosporine,NRo tacrolimus,81 and OKT3 B2 PTLD 
resemble the malignancies found in immune defi-
ciency states,83-S5 including acqUired immunodefi-
ciency syndrome.R6 Originally designated "reticu-
lum cell sarcomas,"87 they constitute a spectrum of 
lymphopoietic neoplasms, of which most are B-cell 
lymphomas88-9o that are highly but not invariably 
associated with Epstein-Barr virus (EBV) infesta-
tionYI-93 Because they are dramatically subject to 
immune surveillance,so the pathogenesis and treat-
ment of these lesions have been of special interest 
to tumor biologists as well as to clinicians. 
Pathogenesis of PTLD 
Immune Suppression 
Heavy immunosuppression, either applied by pro-
tocol or in a management response to rejection, 
usually precedes the appearance of PTLD. Con-
versely, dose reduction or discontinuance of such 
treatment frequently is followed by PTLD regres-
sion. so This is not necessarily followed by rejec-
tion,8o,94 even when treatment is permanently 
stopped,Y5 a finding that cannot be accounted for 
by the simple loss and recovery of immune surveil-
lance. 
Chimerism and Tumor Origin 
We have suggested that organ acceptance under 
immune suppression involves the interaction of a 
persistent small population of migratory ("passen-
ger") donor leukocytes from the allograft (micro chi-
merism) with the leukocytes of the recipient im-
mune system (the two-way paradigm)96-98 (Fig. 6). 
The two-way immune reaction in organ recipients 
consists oflow-grade graft-versus-host (GVH) and 
host-versus-graft (HVG) components. PTLD can 
be viewed as a pathological deviation from this 
joint immunocyte activation, to which powerful 
cofactors are added that act on both populations. 
Because host leukocytes in most organ recipi-
ents vastly outnumber the chimeric donor cells, the 
clinical PTLD are usually of recipient origin99-101 
(Fig. 7). After bone marrow transplantation, in 
which the leukocyte proportions are mirror image, 
almost all PTLD are of donor origin (Fig. 7). The 
occasional exceptions to this generalization usually 
are seen during the early posttransplantation pe-
riod, during which heavy immune suppression is 
administered. 
Immune 
Reaction 
Time after Transplantation 
Figure 6. Contemporaneous HVG and GVH reac-
tions in the two-way paradigm of transplantation 
immunology. After the initial interaction, the evo-
lution of nonreactivity of each leukocyte popula-
tion to the other is seen as a predominantly 
low-grade stimulatory state that may wax and 
wane rather than a deletional one. 
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Recipient 
Immunocytes 
Cytoablated 
Dominant 
Variable 
Dual Immune Systems 
Bone Marrow Transplantation (BM) [j +4 __ • [E] = Donor PTLD 
Organ Transplantation (0) 
W 'II ~ ..... ~__ R/ = Recipient PTLD 
Either BM or 0 
= Exceptions to rule 
Figure 7. Recipient cell populations and their 
relationship to PTLD phenotype after conven-
tional bone marrow versus organ transplantation 
(see text). 
Viral Factors 
The strong association of human PTLD with EBV 
infection has been known for more than 15 
years.80,91-93 This DNA virus is recognized by cyto-
toxic T cells (CTL) whose surveillance of EBV in 
infected B cells lO2- 106 may be facilitated by an 
accessory nonspecific contribution of natural killer 
(NK) cells, 107-109 This defense mechanism explains 
why the vast majority of normal humans harbor 
EBV but do not develop recurrent infectious mono-
nucleosis or B-cell neoplasms. Under immune 
suppression, however, the EBV-infected immuno-
blast is freed from T-cell surveillance, an event of 
particular importance in the development of PTLD 
because of the uniquely potent B-cell-transforming 
quality of the virus. 
The cumulative effect of a double lymphoprolif-
eratiYe drive (i.e., chimerism plus EBV infection) 
in the absence of immune suppression has been 
shown in the South American cotton-top tamarin 
primate species (Saguinus oedipus), in which birth 
normally is of dizygotic twins. Placental fusion 
routinely leads to multilineage chimerism,l](1, III 
similar to that seen in Freemartin cattleY2 These 
chimeric tamarin have fully normal immunological 
reactivity, including alloantigen-driven prolifera-
tive responses and generation of allogeneic speCific 
CTL precursor cells, and they show in vitro evi-
dence of mutual immunological nonreactivity of 
the coexisting cell populationsllo,lll and reciprocal 
acceptance of skin grafts. J 13 The addition of an EBV 
infection causes severe lymphoproliferative dis-
ease, including unequivocally malignant neo-
plasms. 1H-ll6 
Approximately 8% of clinical posttransplanta-
tion lymphomas in humans develop in the ahsence 
of EBV infection. J 17 Beca use these tumors also may 
involute with reduction or discontinuance of im-
mune suppression,lls they extend the possibility of 
therapeutic immune modulation beyond the EBV 
epitope. 
Treatment Algorithms for PTLD 
PTLD occur in all kinds of organ recipients, but the 
highest incidence has been after liver transplanta-
tion. The risk can be reduced at the outset by 
avoiding the use of antithymocyte globulin (ATG) 
and OKT3 in conjunction with other T-cell-
directed agents (i.e., cyclosporine and tacrolimus), 
except as a last resort. The most effective treatment 
of PTLD is discontinuance or drastic reduction of 
immune suppression, The type of allograft influ-
ences the aggressiveness with which this strategy is 
pursued. If a transplanted kidney is allowed to be 
rejected, the PTLD will disappear in essentially all 
cases, allowing drug-free return to dialysis. There is 
little merit in renal recipients in pursuing cyclic 
gyrations of immunosuppressant dosage in re-
sponse to tumor growth on one hand and rejection 
on the other. 
Persistent efforts at immunosuppressant dose 
control rather than complete discontinuance are 
more justifiable in liver, heart, and lung recipients 
for whom "treatment rest" and retransplantation 
may not be feasible. In our pediatric liver trans-
plant program, histopathologically verified PTLD 
was diagnosed in 28 (12.1%) of the 232 consecu-
tive primary allograft recipients treated with tacro-
limus from 1989 through 1994 (Table 3). Although 
5 of the 28 died of PTLD-related complications, 
patient and graft survival (822% at 4 years) are 
essentially the same as in the non-PTLD group. In 
addition to careful monitoring for EBV infection, 
management of the PTLD has been facilitated by 
our policies of arbitrary gradual tacrolimus dose 
reduction and acceptance of lower plasma and 
hlood levels with the passage of time in addition to 
early discontinuation of prednisone therapy (Table 
3) and avoidance of adjunct agents, including 
OKT3 and azathioprine. 
Although complete discontinuation of immuno-
suppression can result in PTLD involution without 
rejection of the transplanted organ, reluctance to 
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Table 3. Primary Live\Transplantation (n""232) in 
ChHdren Receiving Tacrolimus-8ased ItmKrlt;ll'\e 
pupp~ession during1K~~ . 
Months of Follow-up 
3 12 24 36 48 
Survival (%) 
Patient 90.2 86 85 84 84 
Graft 83 79.2 78.2 77.3 77.3 
Tacrolimus (mean) 
Dose (mgld) 5.6 3.3 2.9 2.9 2.4 
Plasma 
Concentration-
(trough ng/mL) 0.84 0.56 0.43 0.4 0.24 
Prednisone (%) 
None 79 82 88 93 91 
:55 9 13 7 5 7 
2:5 mg/d 12 5 5 2 2 
NOTE. N = 232. Age, 5.0 :!: 5.2 (mean:!: SO; 
median, 2.7) years. Mean follow-up, 44 :!: 14.6 
months. 28 patients developed PTLD; 23 (82%) 
survive with their original graft. Principal sites were 
gastrointestinal (9); lymph nodes (8); liver (6); spleen 
(2); and tonsil, skin, and blood (leukemia) (1 each). 
'For approximate whole blood values, multiply x 10. 
jeopardize the graft is a psychological barrier to 
taking this drastic step. Moreover, a response may 
not be seen even with drug discontinuation if prior 
immune suppression has been so severe that recov-
ery of natural surveillance cannot occur in time to 
overtake a rapidly growing neoplasm. Conse-
quently, early multiple-agent lymphoma therapy 
has been recommended if PTLD regression is not 
seen within a few days,u9.122 Because the lym-
phoma protocols call for high doses of drugs that 
are themselves immunosuppressive, their use vari-
ably contravenes the restoration of host immune 
surveillance, upon which survival ultimately de-
pends (Fig. 8). In addition, the opportunity may be 
lost for a systematic search for an appropriate 
reduced dose of conventional immunosuppression 
that may allow PTLD control without rejection of 
the graft. 
Recent developments in cellular immune modu-
lation for bone marrow transplantation have sug-
gested other options. In bone marrow recipients, 
regression of EBV-positive PTLD of donor pheno-
type has been accomplished by infusion of naive 
cytotoxic T lymphocytes obtained from the origi-
nal donor. i2l In an attempt to minimize the atten-
dant risk of GYHD, sorted EBY-specific CTL have 
been used, with arrest of early lymphoproliferation 
in EBV-infected bone marrow recipients at high 
risk from infectious mononucleosis syndromes.124 
Naive recipient leukocytes with which to apply 
the same principles to organ transplantation PTLD 
in mirror image are almost never available. This 
need could be met in three ways: (1) cryopreserva-
tion of pretransplantation peripheral blood mono-
nuclear cells (PBMC) or bone marrow, (2) use of a 
surrogate leukocyte donor HLA identical to the 
recipien t. 125 or (3) functional resurrection of the 
recipient's own PBMC or bone marrow. 
We have had experience with the third option in 
liver, lung. heart. and kidney recipients 2 months 
to 12 years posttransplantation. 118 PBMC were 
obtained by leukopheresis, depleted of leukocytes 
of monocyte/macrophage lineage. and cultured in 
the presence of interleukin 2 for 10 to 11 days. 
Although infusions of the resulting LAK cells 
caused regression of EBY-positive tumors in all 
four such recently reported cases, efficacy could 
not be evaluated in the EBV-negative cases because 
of confounding circumstances. lls 
It must be emphasized that because the LAK 
cells are lineage committed and not self-renewable. 
they provide only a bridge to the ultimate objective 
of natural recipient surveillance. The principal 
value of such treatment will be in those patients 
who are so deeply immunosuppressed that they 
Chemotherapy 
Rejection 
Immune 
Suppression 
PLTD 
Mass 
Time after Transplant3tlon 
Figure 8. Prototypic error of giving lymphoma 
chemotherapy (which is inherently immunosup-
pressive) to a liver transplant recipient whose 
recovery from PTLD depends on restoration of 
immunological tumor surveillance. The abdomi-
nal PTLD mass that involuted after reduction of 
immune suppression regrew with restoration of 
therapy. The error was compounded by initiation 
of CHOPS lymphoma treatment, after which dis-
continuance of tacrolimus and prednisone was 
no longer effective. 
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cannot recover natural immune surveillance 
promptly. Retardation of immunological recovery 
with chemotherapy or high-dose radiotherapy 
works at cross-purposes with the global strategy of 
surveillance restoration and should be used, if at 
all, only when all else has failed. 
Is Immunization Possible for PTLD? 
Prior vaccination of cotton-top tamarins with ei-
ther EBV or its recombinant proteins protects the 
animals against subsequent development of EBV-
induced malignant Jymphomasy6.12H Such an ap-
proach might be used to immunize EBV-negative 
human organ allograft recipients \>yho are at predict-
ably high risk from EBV-associated PTLD (e.g., 
liver, intestinal, or llluitivisceral transplant candi-
dates I29). The immunity of EEV-seropositive pa-
tients might also be boosted by vaccination with 
autologous irradiated EBV-transformed B-cell blasts. 
As with other vaccination protocols, repeated 
exposure to the antigen may be required to attain a 
protective level of immunization. Because vaccina-
tion of EBV-negative transplant candidates could 
have a theoretical risk of accidental transplantation 
of autologous EBV-exposed antigen-presenting cells, 
immunization of these patients should be with 
recombinant EBY peptides only. However, patients 
who are already EBV seropositive could have their 
immunological memory to EBY-transformed cells 
boosted with irradiated EEY-transformed cells. This 
has been shown to be feasible in mouse experi-
ments without a risk of SY40 tumor engraft-
menL 110,l31 
Conclusions 
Our fledgling Journal can be vitalized from the 
same wellsprings that have been tapped but not 
exhausted in the evolution of liver transplantation 
to its present state. Examples with historical roots 
that continue to generate interest have been de-
scribed. These could be categorized as physiological! 
metabolic, anatomic/technical, and oncological. 
However, no effort has been made to describe the 
full spectrum of potential clinical and basic scien-
tific subjects that could be considered by the 
editors for inclusion. 
For example, no mention has been made of the 
virtually limitless areas of infectious disease or of 
xenotransplantation. The role of liver transplanta-
tion in exposing the meaning of immunological 
tolerance and how to achieve it also is too large to 
briefly summarize. It would be equally futile to 
dwell on the advances in pharmacological immune 
suppression of the last two decades other than to 
note that these were driven primarily by clinical 
research designed to improve liver transplanta-
tion.l(l,l32.140 Management improvements were then 
adapted with only minor variations for transplanta-
tion of the kidney, heart, and other organs. 
No one understands the need for di.versification 
of articles better than the editors of Liver Transplan-
tation and Surgery. The key word for advancement 
of this objective is "liver," rather than either "trans-
plantation" or "surgery." This inSight notwithstand-
ing, the editors will be powerless to shape and 
strengthen the Journal without receipt of fine 
original manuscripts. The prime responsibility [or 
this rests at present with liver transplant surgeons, 
hepatologists, and anesthesiologists. Because the 
Journal was their brainchild, failure to broaden its 
base beyond transplantation will redound to the 
discredit of these elite but relatively small corps of 
specialists. 
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